Kop Therapeutics

KOP Therapeutics is a Canadian biotech company based in Vancouver, BC, dedicated to developing affordable, non-toxic mRNA cancer therapies aimed at inducing cancer cell death with minimal side effects. The company holds an exclusive worldwide license from Thomas Jefferson University and has relocated its research operations to streamline the development process.

Focused on targeted immunotherapy, KOP Therapeutics utilizes a novel AI-enabled drug design platform that selectively targets cancer cells while sparing healthy cells. Their flagship product, KOP101, aims to silence critical cancer genes, thereby preventing tumor growth and recurrence, with promising applications across various cancer types.

Generated from the website